Total Synthesis and Metabolic Stability of Hispidulin and Its *d*-Labelled Derivative

Liang-Chieh Chen [1,2] ![iD], Kai-Cheng Hsu [3], Lih-Chu Chiou [4,5], Hui-Ju Tseng [1,6] and Wei-Jan Huang [1,6,7,8,]*

[1] Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan; pigjay15@gmail.com (L.-C.C.); d343105007@tmu.edu.tw (H.-J.T.)
[2] School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan
[3] Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan; piki@tmu.edu.tw
[4] Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Taipei 110, Taiwan; lcchiou@ntu.edu.tw
[5] Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
[6] Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan
[7] Program for the Clinical Drug Discovery from Botanical Herbs, Taipei 110, Taiwan
[8] School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan
* Correspondence: wjhuang@tmu.edu.tw; Tel.: +886-2-27361661 (ext. 6152)

Abstract: Hispidulin is a naturally occurring flavone known to have various Central nervous system (CNS) activities. Proposed synthetic approaches to synthesizing hispidulin have proven unsatisfactory due to their low feasibility and poor overall yields. To solve these problems, this study developed a novel scheme for synthesizing hispidulin, which had an improved overall yield as well as more concise reaction steps compared to previous methods reported. Additionally, using the same synthetic strategy, *d*-labelled hispidulin was synthesized to investigate its metabolic stability against human liver microsome. This work may produce new chemical entities for enriching the library of hispidulin-derived compounds.

1. Introduction

Flavonoids, a group of polyphenolic compounds, occur ubiquitously in plants. These compounds have generally been categorized into several classes, including chalcones, flavonols, flavones, isoflavones, flavan-3-ols, neoflavones, flavanones and anthocyanins, based on their chemical structures [1]. In addition to the diverse structures, they also have many biological properties, such as antioxidative [2], anti-inflammatory [3], antimicrobial [4], anticonvulsant [5], antidepressant [6] and anticancer [7] activities. These facts indicate the important role of flavonoid compounds.

Our recent clinical case report described a patient with a refractory chronic motor tic disorder who dramatically improved after taking the leaf juice of a local herb, *Clerodendrum inerme* (L.) Gaertn (*CI*) [8]. The ethanol extract of *CI* leaf alleviated methamphetamine-induced hyperlocomotion (MIH) as a mouse model of motor tic [9]. Using a bioassay-guided purification procedure in this animal model, we further isolated the constituents from *CI* leaf extract to identify a flavone hispidulin (6-methoxy-4′,5,7-trihydroxyflavone) to be the main active ingredient (Figure 1) [9]. Hispidulin significantly attenuated MIH and even in amounts up to 100 mg/kg was incapable of affecting spontaneous locomotor activity or performance in mice [9]. Importantly, hispidulin had no hit on human ether-à-go-go-related gene (hERG) channels, an undesirable target in drug development [10].


Hispidulin

**Figure 1.** The chemical structure of hispidulin.

Hispidulin is widely distributed in Asteraceae [11–14] and some of the Lamiaceae [15]. Further assays for screening towards 92 target proteins associated with Central nervous system (CNS) diseases indicated that hispidulin formed strong bonds with GABA$_A$ receptors (IC$_{50}$ = 0.73−1.78 μM) and inhibited catecholamine-*O*-methyl-transferase (COMT) (IC$_{50}$ 1.32 μM) [10]. By acting as a positive allosteric modulator (PAM), it enhanced cerebellar α$_6$GABA$_A$ receptor activity. Studies revealed some C6-substituted flavones are identified to be PAMs of GABA$_A$ receptors [16,17]. The results of a structure–activity relationship (SAR) study indicated the C6 substituent in flavones greatly contributes to activity [10].

Because of its interesting biological activity, several research groups have developed synthetic approaches to hispidulin [18–23]. For example, Shen and coworkers developed a strategy for semisynthesis of hispidulin in seven reaction steps by using a naturally occurring scutellarin (Scheme 1) [22]. Although this method is concise and has an overall yield as high as 10.7% [22], the researchers showed that, upon the large-scale synthesis of compound **1**, the protection of the catechol moiety of scutellarein using dichlorodiphenylmethane at 175 °C failed [20,23]. A seven-step synthesis route developed by Lin and coworkers solved this problem but reduced the overall yield to 7.1% (Scheme 1) [20]. Zhang and coworkers then developed a scheme that only required four reaction steps (Scheme 1). Nonselective MOM (methoxymethyl) protection of scutellarein caused the overall yield of the synthesis of hispidulin to be decreased (6.3%) [23]. Despite the satisfactory overall yield of these strategies, the tedious purification procedure required to isolate scutellarin from plants limits their use for large-scale preparation of hispidulin.

Kavvadias and coworkers developed a method synthesizing hispidulin from 2,4,6-trihydroxyacetophenone compound **6** in nine reaction steps (Scheme 2). However, the overall yield of this method is very limited (1.1%) [18]. We recently developed a feasible and reproducible approach for synthesizing hispidulin (Scheme 3) [21]. This method slightly improved the overall yield due to the low yield of Friedel–Crafts acetylation of compound **8** as well as unsatisfactory regioselective MOM protection of compound **9**. These facts motivated us to investigate an efficient and high-yield route to synthesize hispidulin.

Scheme 1. Synthesis of hispidulin starting from scutellarin.

Scheme 2. Synthesis of hispidulin by Kavvadias and coworkers.

Scheme 3. Synthesis of hispidulin in our previous study.

Deuterium is a stable isotope of hydrogen. Because deuterium has a stronger chemical bond with carbon than hydrogen, deuterium-labelled compounds can affect the absorption, distribution, metabolism and toxicology of their counterpart compound [24,25]. The Food and Drug Administration (FDA) recently approved the first deuterated drug, deutetrabenazine, for treating involuntary writhing movements or chorea in Huntington's disease [26]. Deuterium incorporation of tetrabenazine markedly increased its half-life and area under the curve (AUC) in plasma [27]. Study showed that the pig caecal microflora metabolized hispidulin to scutellarein due to *O*-demethylation at the C6 position [28]. This result suggested that replacement of OCH_3 of this position of hispidulin using OCD_3 may reduce its metabolic liability. Therefore, this study replaced $C6-OCH_3$ in hispidulin with $C6-OD_3$ to investigate whether such modification allows enhancement of the metabolic stability. Notably, introducing deuterium into hispidulin leads to a new chemical entity (NCE) that meets the criteria for a 505(b) (2) patent application [27].

The new hispidulin synthesis scheme developed in this study is more feasible compared to all methods previously reported. In particular, it had the highest overall yield, which may help to synthesize $C6-OCH_3$-containing hispidulin derivatives. The same strategy can also be used to synthesize *d*-labelled hispidulin. The microsome stability of hispidulin and its deuterium counterpart were compared.

2. Results and Discussion

2.1. Retrosynthetic Analysis of Hispidulin

Figure 2 shows the retrosynthetic analysis to successfully synthesize hispidulin. Hispidulin can be produced from compound **I** via debenzylation and oxidative cyclization. Compound **I** is derived from compound **II** and commercially available compound **III**, which are used to conduct Claisen–Schmidt condensation and deprotection of MOM (methoxymethoxy). Compound **II** in turn can be prepared from compound **IV** via methylation. Compound **IV** is considered to be the key intermediate that possesses two different protecting groups as well as acetyl and hydroxy moieties. Selective Bayer–Villiger reaction of compound **V** provided compound **IV**. Compound **V** is prepared from compound **VI** via Stille coupling. Benzylation and regioselective iodination of compound **VII** gives compound **VI**. Starting from commercially available compound **7**, Compound **VII** is synthesized via selective MOM protection.

**Figure 2.** Retrosynthetic analysis of hispidulin.

2.2. Synthesis of Hispidulin

Scheme 4 shows a synthetic approach originally developed for hispidulin. Using compound **6** as the starting material, selective MOM protection towards its C4- and C6-OH gave compound **11**. First, *N*-bromosuccinimide (NBS) was used for bromination of C3 of compound **11**; however, only undesirable C3 and C5 dibromination occurred. Alternatively, compound **11**, when reacted with I_2 in the presence of Lewis acid CF_3CO_2Ag, provided selectively iodinated product **12** in the high yield (90%). The experimental result resulted from the difference of steric hindrance between C3 and C5 upon using the more bulky reagent I_2. Benzylation of compound **12** generated compound **13**. Next, several reported oxidation methods were used [29–31] in attempts to convert the iodide group of compound **13** into phenol. These oxidation catalysts included CuI, Cu and Pd, as shown in Table 1. Reaction using Pd_2dba_3 coupled with the ligand 2-di-*tert*-butylphosphino-2′,4′,6′-triisopropylbiphenyl (*t*BuXPhos) gave compound **14**, but its yield was poor (27%). Despite the use of microwave irradiation, the yields were incapable of being improved. Instead, Claisen–Schmidt condensation of compound **13**, reacted with 4-(benzyloxy)benzaldehyde prior to selective deprotection of MOM group in the presence of HCl, gave chalcone **15**. The selective deprotection reaction can be manipulated by decreasing the reaction time to avoid further MOM deprotection of C4. Oxidative cyclization of compound **15** in the presence of catalytic I_2 provided flavone **16**. Notably, excess I_2 caused an undesirable retro-aldol reaction that gave C4- and C6-deprotected compound **13**. Treatment of catalytic $Pd(PPh_3)_4$ and tributyl(1-ethoxyvinyl)tin converted compound **16** to compound **17** through the Stille reaction. Baeyer–Villiger oxidation followed by basic hydrolysis of compound **17** by using H_2O_2 or *m*-chloroperoxybenzoic acid (MCPBA) [32] failed to give expected product **18**.

Table 1. Attempts towards the oxidation of aryl halide **13**.

| Entry	Catalyst	Ligand	Base	Solvent	T (°C)	Yield (%)
1	CuI	1,10-Phenanthroline	KOH	DMSO–H_2O	100	trace
2	Cu	-	NaOH	H_2O	100	trace
3	Cu	-	NaOH	DMSO–H_2O	100	trace
4	Pd_2dba_3	*t*BuXPhos	KOH	Dioxane–H_2O	100	27
5	Pd_2dba_3	*t*BuXPhos	KOH	Dioxane–H_2O	70	14
6	Pd_2dba_3	*t*BuXPhos	KOH	Dioxane–H_2O	100 [1]	26
7	Pd_2dba_3	*t*BuXPhos	KOH	Dioxane–H_2O	100 [2]	23
8	Pd_2dba_3	*t*BuXPhos	KOH	DMF	100 [1]	trace

[1] Microwave reaction: 100 W, 20 min; [2] microwave reaction: 120 W, 20 min.

Scheme 4. Initial attempt for the synthesis of hispidulin. *Reagents and conditions*: (**a**) MOMCl, DIPEA, CH_2Cl_2, 0 °C, 64%; (**b**) CF_3COOAg, I_2, CH_2Cl_2, 0 °C, 90%; (**c**) K_2CO_3, BnBr, DMF, 0 °C, 99%; (**d**) Pd_2dba_3, *t*BuXPhos, KOH, dioxane–H_2O, 90 °C, 27%; (**e**) (1) BnOPhCHO, KOH, EtOH, H_2O, 0 °C; (2) c-HCl, MeOH, THF, 0 °C, 77%; (**f**) I_2, DMSO, 120 °C, 32%; (**g**) tributyl(1-ethoxyvinyl)tin, $Pd(PPh_3)_4$, dioxane, 100 °C, 61%.

Thus, we developed a new synthesis (Scheme 5) for hispidulin using the retrosynthetic analysis as shown in Figure 2. First, 2,4,6-trihydroxybenzaldehyde **7** reacted with MOMCl gave the bis(methoxymethoxy)-protected compound **20**. Regioselective iodination of compound **20** prior to reaction with BnBr produced compound **21**. The chemical structure of compound **21** was confirmed by rotating frame nuclear Overhauser effect spectroscopy (ROESY) spectrum. Figure 3 shows the key correlation of H-5 (δ_H 6.84) to H-2‴ (δ_H 3.52), H-2⁗ (δ_H 3.54), H-1‴ (δ_H 5.29) and H-1⁗ (δ_H 5.32); and

H-1′ (δ_H 10.30) to H-2′′′′ (δ_H 3.54), H-1′′ (δ_H 4.99) and H-1′′′′ (δ_H 5.32) (Supplementary Materials). Stille coupling of compound **21** produced compound **22**. Table 2 shows how tributyl(1-ethoxyvinyl)tin was used to optimize Stille coupling. First, catalyst Pd(PPh$_3$)$_4$ was used in dioxane at 100 °C. The reaction had a satisfactory yield (68%), but the reaction time was up to 30 h. Replacement of the solvent by toluene led to the reaction time decreasing to 24 h. Further experiments using palladium catalysts such as PdCl$_2$(PPh$_3$)$_2$ and Pd(dppf)Cl$_2$ in dioxane or toluene showed that PdCl$_2$(PPh$_3$)$_2$ significantly improved the yield and decreased the reaction time. In particular, PdCl$_2$(PPh$_3$)$_2$ coupled with toluene not only gave the highest yield, but also had the lowest reaction time. Baeyer–Villiger oxidation and basic hydrolysis of compound **22** afforded compound **14**. Methylation of compound **14** using CH$_3$I gave compound **23a**. Claisen–Schmidt condensation of compound **23a** with 4-(benzyloxy)benzaldehyde prior to MOM deprotection produced chalcone **24a**. Cyclization of compound **24a** in the presence of catalytic I$_2$ generated flavone **25a**. Although debenzylation of compound **25a** catalyzed by 10% Pd–C did not yield hispidulin, a reaction using BCl$_3$ at −80 °C successfully converted compound **25a** into hispidulin. The chemical structure of hispidulin was identified as judged by 2D-NMR analyses. Figure 4 shows the key correlation in the ROESY spectrum of hispidulin that 5-OH (δ_H 13.07) was correlated to 6-OMe′′′ (δ_H 3.74) and H-8 (δ_H 6.59) was correlated to H-2′ and H-6′ (δ_H 7.92). Additionally, the HMBC spectrum showed that 5-OH (δ_H 13.07) correlated to C-5 (δ_C 152.8), C-6 (δ_C 131.4), C-7 (δ_C 157.3), C-9 (δ_C 152.4) and C-10 (δ_C 104.1); H-8 (δ_H 13.07) correlated to C-6 (δ_C 131.4), C-7 (δ_C 157.3), C-9 (δ_C 152.4) and C-10 (δ_C 104.1); 6-OMe-H (δ_H 3.74) correlated to C-6 (δ_C 131.4) (Supplementary Materials). The ^{1}H- and ^{13}C-NMR data of synthesized hispidulin were similar to those of hispidulin previously isolated (Supplementary Materials) [33].

Scheme 5. Synthesis of hispidulin and *d*-hispidulin. *Reagents and conditions*: (**a**) MOMCl, DIPEA, CH$_2$Cl$_2$, 0 °C, 80%; (**b**) (1) CF$_3$COOAg, I$_2$, CH$_2$Cl$_2$, 0 °C; (2) K$_2$CO$_3$, BnBr, DMF, 0 °C, 89%; (**c**) tributyl(1-ethoxyvinyl)tin, PdCl$_2$(PPh$_3$)$_2$, toluene, 100 °C, 83%; (**d**) (1) MCPBA, CH$_2$Cl$_2$, 0 °C; (2) 10% NaOH$_{(aq)}$, MeOH, 68%; (**e**) **23a**: CH$_3$I, K$_2$CO$_3$, acetone, 56 °C, 92%; **23b**: CD$_3$I, K$_2$CO$_3$, acetone, 56 °C, 93%; (**f**) (1) BnOPhCHO, KOH, EtOH, H$_2$O, 0 °C; (2) c-HCl, MeOH, THF, 0 °C; **24a**: 92%, **24b**: 81%; (**g**) I$_2$, DMSO, 120 °C, **25a**: 93%, **25b**: 79%; (**h**) 1M BCl$_3$ in hexane; CH$_2$Cl$_2$, −80 °C, hispidulin: 85%, *d*-hispidulin: 80%.

Figure 3. Key rotating frame nuclear Overhauser effect spectroscopy (ROESY) correlations of compound **21**.

Table 2. Optimization of reaction condition for Stille coupling of compound **21**.

| Entry	Catalyst	Solvent	Yield (%)	Reaction Time (h)
1	$Pd(PPh_3)_4$	Dioxane	68	30
2	$Pd(PPh_3)_4$	Toluene	70	24
3	$PdCl_2(PPh_3)_2$	Dioxane	73	20
4	$PdCl_2(PPh_3)_2$	Toluene	83	10
5	$Pd(dppf)Cl_2$	Dioxane	34	78
6	$Pd(dppf)Cl_2$	Toluene	53	43

Figure 4. Key ROESY and HMBC correlations of hispidulin.

2.3. Synthesis of d-Hispidulin

The synthesis of *d*-hispidulin is described in Scheme 5. Methylation of compound **14** using CD_3I gave compound **23b**. The same method to hispidulin was used to synthesize *d*-labelled hispidulin starting from compound **23b**. Due to the absence of a proton signal of the CD_3O group in the ^{1}H-NMR spectra of the *d*-containing intermediate compounds **23b**, **24b**, **25b** and *d*-hispidulin, these compound structures were identified depending on the ^{13}C-NMR spectra without ^{1}H decoupling and the mass technique. The ^{13}C-NMR spectra revealed a characteristic multiplet splitting pattern of the ^{13}C signal for the CD_3O group in compounds **23b**, **24b**, **25b** and *d*-hispidulin. The mass spectra also supported chemical structures of these *d*-labelled compounds. All synthesized compounds had an estimated purity of at least 98% as determined by HPLC analysis (Supplementary Materials).

2.4. Comparison of Hispidulin Synthesis Methods

Strategies for synthesizing hispidulin can be classified as semisynthesis and total synthesis strategies. The starting material used in most semisynthetic methods is scutellarin, which is a natural product. Table 3 shows that the semisynthesis routes had fewer reaction steps compared to the total synthesis methods; however, they need tedious isolation procedures for scutellarin, which limits the scale for further chemical modification. Furthermore, their overall yields are only 6.3–10.7% [20,22,23]. For total synthesis, Kavvadias and coworkers developed a nine-step synthesis approach. The starting material used in this method is commercially available 2,4,6-trihydroxyacetophenone. Although this method solves the issue of the source for starting material, its drawback is low overall yield [18]. We previously developed a feasible route of hispidulin synthesis that has an overall yield comparable

to that of the method developed by Kavvadias and coworkers [21]. This present study further made the reaction steps more concise. In particular, the synthetic scheme showed the highest overall yield of all approaches to synthesize hispidulin.

Table 3. Comparison of hispidulin synthesis methods.

Research Group	Synthesis Route	Reaction Steps	Overall Yield (%)
Shen and coworkers	Semisynthesis	Seven	10.7
Lin and coworkers	Semisynthesis	Seven	7.1
Zhang and coworkers	Semisynthesis	Four	6.3
Kavvadias and coworkers	Total synthesis	Nine	1.1
Chao and coworkers	Total synthesis	Ten	1.6
This study	Total synthesis	Eight	26.9

2.5. Human Liver Microsome Stability

Metabolic stability is associated with susceptibility of compounds to biotransformation. Metabolic half-life ($t_{1/2}$) and intrinsic clearance (CL_{int}) was compared between hispidulin and *d*-hispidulin by testing these synthesized compounds in a human liver microsome stability assay. The study revealed that FDA-approved deuterated agent deutetrabenazine had a $t_{1/2}$ (8.6 h) superior to tetrabenazine (4.8 h). In addition to $t_{1/2}$, the AUC of deutetrabenazine (542 ng·hr/mg) was also higher than that of its counterpart compound (261 ng·hr/mg) [27]. In contrast, the experimental results indicated hispidulin and *d*-hispidulin had no significant difference in $t_{1/2}$ and CL_{int} (Table 4), which suggested that the C6-OMe of hispidulin is resistant to be modified by the human liver microsome. The metabolic site of hispidulin in the human liver microsome is worthy of further study.

Table 4. Human liver microsome stability of hispidulin and *d*-hispidulin.

Compound	Half-Life (min)	CL_{int} [1] (mL/min/mg Protein)
Hispidulin	46	0.0298
d-Hispidulin	43	0.0325
Testosterone	19	0.0727

[1] Intrinsic clearance (CL_{int}) was calculated based on $CL_{int} = k/P$, where k is the elimination rate constant and P is the protein concentration in the incubation.

The experiments showed that this method of synthesizing hispidulin and its *d*-labelled derivative is highly feasible. Specifically, it increases overall yield compared to previous methods. The $t_{1/2}$ and intrinsic clearance of these two compounds were identified as well. Overall, this synthetic route can be applied to produce 6-OMe-containing hispidulin derivatives as new chemical entities for investigating their biological activities.

3. Experimental Section

3.1. General Information

The NMR spectra (^{1}H- and ^{13}C-NMR, ROESY, HSQC and HMBC) were obtained with a Bruker AV500 using standard pulse programs. The MS data were recorded with a Finnigan Mat TSQ-7000 mass spectrometer (HR–ESI–MS) (Thermo, Ringoes, NJ, USA). The HPLC was performed on a C_{18} column (150 mm × 4.6 mm, Ascentis) by using an L-2130 pump (Hitachi, Ibaraki, Japan) and a UV/vis L-2420 detector (Hitachi, Ibaraki, Japan). The column chromatography was performed on silica gel (70-230 mesh, Merck, Darmstadt, Germany). All TLC analyses were performed on silica gel plates (KG60-F254, Merck, Darmstadt, Germany). Reagents and materials were used without further purification and chemicals were purchased from ACROS (Geel, Belgium). Dry dichloromethane was distilled from CaH_2 under nitrogen atmosphere. MOMCl was acquired from TCI (Tokyo, Japan), and 2,4,6-trihydroxybenzaldehyde was purchased from Alfa Aesar (Heydham, UK).

3.2. Chemistry

2-Hydroxy-4,6-bis(methoxymethoxy)benzaldehyde (**20**). To a solution of compound **7** (10 g, 64.9 mmol) in CH_2Cl_2 (200 mL) was added DIPEA (28.3 mL, 162.2 mmol). The resulting mixture was stirred for 10 mins in an ice-bath under N_2. MOMCl (10.8 mL, 142.7 mmol) was added dropwise to the reaction mixture by addition funnel. The reaction mixture was warmed to room temperature (rt) and stirred for 3 h. The mixture was concentrated in vacuo. The residue was diluted with EtOAc (100 mL) and washed with distilled H_2O (3 × 80 mL). The organic layer was dried over Na_2SO_4, filtered and removed in vacuo. The residue was purified by silica gel chromatography (EtOAc:*n*-hexane = 1:9) to give compound **20** (12.3 g, 80%), a light-yellow microcrystalline powder; ^{1}H-NMR ($CDCl_3$, 300 MHz) δ 12.29 (1H, s), 10.16 (1H, s), 6.25 (1H, d, *J* = 2.1 Hz), 6.23 (1H, d, *J* = 2.1 Hz), 5.24 (2H, s), 5.18 (2H, s), 3.51 (3H, s), 3.47 (3H, s); ^{13}C-NMR ($CDCl_3$, 125 MHz) δ 192.1, 165.6, 165.5, 161.2, 106.9, 96.6, 94.6, 94.1, 94.0, 56.6, 56.5; HR–ESI–MS *m/z* 243.0858 [M + H]+ (calcd. for $C_{11}H_{15}O_6$, 243.0863).

2-Benzyloxy-3-iodo-4,6-bis(methoxymethoxy)benzaldehyde (**21**). To a mixture of compound **20** (7.2 g, 29.6 mmol) and CF_3CO_2Ag (7.8 g, 35.5 mmol) in CH_2Cl_2 (150 mL) at 0 °C was added I_2 (8.3 g, 32.5 mmol) in CH_2Cl_2 (200 mL) dropwise by an addition funnel over 2 h. The reaction mixture was warmed to rt and stirred for 3 h. Then, saturated $Na_2S_2O_{3(aq)}$ (50 mL) was added and the mixture was washed with distilled H_2O (3 × 100 mL). The organic layer was dried over Na_2SO_4, filtered and removed in vacuo. The residue was dissolved in DMF (100 mL) and then K_2CO_3 (7.2 g, 51.8 mmol) was added. Benzyl bromide (460 μL, 3.9 mmol) was added dropwise to the mixture by an addition funnel at 0 °C. The resulting solution was warmed to rt and stirred for 3 h. The mixture was diluted with EtOAc (300 mL) and washed with distilled H_2O (3 × 00 mL). The organic layer was dried over Na_2SO_4, filtered and removed in vacuo. The residue was purified by silica gel chromatography (EtOAc:*n*-hexane = 1:5) to give compound **21** (12.1 g, 89%), a white microcrystalline powder; ^{1}H-NMR ($CDCl_3$, 300 MHz) δ 10.30 (1H, s), 7.66 (2H, dd, *J* = 1.8, 8.1 Hz), 7.45–7.36 (3H, m), 6.84 (1H, s), 5.32 (2H, s), 5.29 (2H, s), 4.99 (2H, s), 3.54 (3H, s), 3.52 (3H, s); ^{13}C-NMR ($CDCl_3$, 125 MHz) δ 187.2, 161.9, 161.8, 161.6, 136.1, 129.0, 128.5, 128.4, 115.5, 98.2, 95.2, 94.9, 78.5, 56.7; HR–ESI–MS *m/z* 459.0294 [M + H]+ (calcd. for $C_{18}H_{20}O_6I$, 459.0299).

3-Acetyl-2-benzyloxy-4,6-bis(methoxymethoxy)benzaldehyde (**22**). To a mixture of compound **21** (5 g, 10.9 mmol) and $PdCl_2(PPh_3)_2$ (766 mg, 1.1 mmol) in toluene (200 mL) was added tributyl(1-ethoxyvinyl)tin (5.5 mL, 16.4 mmol). The resulting solution was heated to 100 °C and stirred for 12 h. After cooling to rt, the reaction mixture was acidified with 1 M HCl (50 mL) and stirred for 30 min. The mixture was diluted with EtOAc (200 mL) and washed with distilled H_2O (3 × 100 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc:*n*-hexane = 1:4) to give compound **22** (3.5 g, 83%), a yellow microcrystalline powder; ^{1}H-NMR ($CDCl_3$, 300 MHz) δ 10.37 (1H, s), 7.48 (2H, dd, *J* = 1.8, 7.8 Hz), 7.41–7.33 (3H, m), 6.80 (1H, s), 5.29 (2H, s), 5.24 (2H, s), 4.96 (2H, s), 3.53 (3H, s), 3.49 (3H, s), 2.43 (3H, s); ^{13}C-NMR ($CDCl_3$, 125 MHz) δ 200.9, 187.3, 162.1, 159.3, 158.4, 136.1, 129.0, 128.8, 128.6, 128.5, 128.4, 121.8, 114.3, 97.5, 95.0, 94.5, 79.1, 56.8, 32.5; HR–ESI–MS *m/z* 375.1432 [M + H]+ (calcd. for $C_{20}H_{23}O_7$, 375.1438).

2-Benzyloxy-3-hydroxy-4,6-bis(methoxymethoxy)acetophenone (**14**). To a solution of 70% MCPBA (6.8 g, 27.6 mmol) in dry CH_2Cl_2 (100 mL) at 0 °C was added compound **22** (3.4g, 9.2 mmol) in CH_2Cl_2 (100 mL) dropwise by an addition funnel over 1 h. The resulting solution was warmed to rt and stirred for 8 h. Then, saturated $Na_2S_2O_{3(aq)}$ (30 mL) was added and the reaction mixture was washed with distilled H_2O (3 × 100 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated in vacuo. The residue was dissolved in MeOH (80 mL) and 10% $NaOH_{(aq)}$ (60 mL) was added. The resulting solution was stirred at rt for 1.5 h. The mixture was diluted with EtOAc (250 mL) and washed with distilled H_2O (3 × 100 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc:*n*-hexane = 1:4) to give compound **14** (2.3 g, 68%), a light-yellow oil; ^{1}H-NMR ($CDCl_3$, 300 MHz) δ 7.44 (2H, dd, *J* = 1.8,

8.1 Hz), 7.40–7.32 (3H, m), 6.76 (1H, s), 5.61 (1H, s), 5.21 (2H, s), 5.08, (2H, s), 5.06 (2H, s), 3.53 (3H, s), 3.46 (3H, s), 2.45 (3H, s); ^{13}C-NMR (CDCl$_3$, 125 MHz) δ 201.3, 146.6, 146.2, 143.2, 136.9, 134.9, 128.5, 128.3, 122.1, 100.4, 96.0, 95.8, 76.3, 56.6, 56.3, 32.6; HR–ESI–MS *m/z* 363.1431 [M + H]$^+$ (calcd. for C$_{19}$H$_{23}$O$_7$, 363.1438).

2-Benzyloxy-3-methoxy-4,6-bis(methoxymethoxy)acetophenone (**23a**). To a mixture of compound **14** (587 mg, 1.6 mmol) and K$_2$CO$_3$ (1.1 g, 8.1 mmol) in acetone (20 mL) was added CH$_3$I (0.5 mL, 8.1 mmol). The resulting solution was heated to 56 °C and stirred for 5 h. The reaction mixture was concentrated in vacuo, diluted with EtOAc (100 mL) and washed with distilled H$_2$O (3 × 50 mL). The organic layer was dried over Na$_2$SO$_4$, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc:*n*-hexane = 1:5) to give compound **23a** (558 mg, 92%), a white microcrystalline powder; ^{1}H-NMR (CDCl$_3$, 300 MHz) δ 7.42 (2H, dd, *J* = 2.0, 8.3 Hz), 7.40–7.32 (3H, m), 6.76 (1H, s), 5.23 (2H, s), 5.11 (2H, s), 5.07 (2H, s), 3.85 (3H, s), 3.53 (3H, s), 3.46 (3H, s), 2.38 (3H, s); ^{13}C-NMR (CDCl$_3$, 125 MHz) δ 200.6, 151.8, 149.4, 149.2, 137.9, 136.7, 128.1, 128.0, 127.7, 121.4, 99.6, 95.0, 94.9, 76.0, 60.8, 56.0, 55.9, 32.1; HR–ESI–MS *m/z* 377.1587 [M + H]$^+$ (calcd. for C$_{20}$H$_{25}$O$_7$, 377.1595).

2-Benzyloxy-3-[^{2}H$_3$]-methoxy-4,6-bis(methoxymethoxy)acetophenone (**23b**). Following the procedure as described for compound **23a**, reaction of compound **14** (1.8 g, 4.8 mmol), K$_2$CO$_3$ (3.3 g, 24.2 mmol), CD$_3$I (1.5 mL, 24.2 mmol) in acetone (40 mL) gave compound **23b** (1.7 g, 93%), a white microcrystalline powder; ^{1}H-NMR (CDCl$_3$, 300 MHz) δ 7.42 (2H, dd, *J* = 2.1, 8.4 Hz), 7.39–7.31 (3H, m), 6.76 (1H, s), 5.23 (2H, s), 5.11 (2H, s), 5.07 (2H, s), 3.53 (3H, s), 3.46 (3H, s), 2.38 (3H, s); ^{13}C-NMR (CDCl$_3$, 125 MHz) δ 200.6, 151.8, 149.4, 149.2, 137.8, 136.7, 128.1, 128.0, 127.7, 121.4, 99.6, 95.0, 94.9, 76.0, 56.0, 55.9, 32.1; HR–ESI–MS *m/z* 380.1775 [M + H]$^+$ (calcd. for C$_{20}$H$_{22}$D$_3$O$_7$, 380.1783).

(E)-1-(2-Benzyloxy-4,6-dihydroxy-3-methoxyphenyl)-3-(4-benzyloxyphenyl)prop-2-en-1-one (**24a**). To a solution of **23a** (545 mg, 1.45 mmol) and 4-benzyloxybenzaldyde (615 mg, 2.9 mmol) in EtOH (20 mL) was added KOH (813 mg, 14.5 mmol) in EtOH–H$_2$O (3 mL:3 mL) dropwise by addition funnel at 0 °C over 30 min. The resulting solution was warmed to rt and stirred for 24 h. The mixture was diluted with distilled H$_2$O (50 mL) and washed with EtOAc (3 × 50 mL). The organic layer was dried over Na$_2$SO$_4$, filtered and concentrated in vacuo. MeOH–THF (14.5 mL:14.5 mL) and 12 M HCl (0.7 mL) was added to the residue at 0 °C. The resulting solution was warmed to rt and stirred for 8 h. The reaction mixture was diluted with distilled H$_2$O (50 mL) and washed with EtOAc (3 × 50 mL). The organic layer was dried over Na$_2$SO$_4$, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc:*n*-hexane = 1:4) to give **24a** (641 mg, 92%), a microcrystalline powder; ^{1}H-NMR (DMSO-*d$_6$*, 300 MHz) δ 12.92 (1H, s), 10.52 (1H, s), 7.59 (2H, s), 7.48–7.45 (2H, m), 7.44–7.37 (5H, m), 7.32–7.29 (5H, m), 6.94 (2H, d, *J* = 8.8 Hz), 6.21 (1H, s), 5.16 (2H, s), 5.06 (2H, s), 3.77 (3H, s); ^{13}C-NMR (DMSO-*d$_6$*, 125 MHz) δ 192.0, 160.2, 159.6, 157.7, 153.1, 143.0, 136.7, 136.6, 134.4, 130.3, 128.5, 128.4, 128.3, 128.2, 128.0, 127.8, 127.4, 124.6, 115.2, 109.0, 99.7, 75.7, 69.4, 60.7; HR–ESI–MS *m/z* 483.1795 [M + H]$^+$ (calcd. for C$_{30}$H$_{27}$O$_6$, 483.1802).

(E)-1-(2-Benzyloxy-4,6-dihydroxy-3-[^{2}H$_3$]methoxyphenyl)-3-(4-benzyloxyphenyl)prop-2-en-1-one (**24b**). According to the procedure as described for compound **24a**, reaction of compound **23b** (1.0 g, 2.6 mmol), 4-benzyloxybenzaldyde (1.1 g, 5.3 mmol) and KOH (1.5 g, 26.4 mmol) in EtOH (60 mL) followed by treatment of 12 M HCl (1.3 mL) and MeOH–THF (26.4 mL:26.4 mL) gave compound **24b** (1.0 g, 81%), a yellow microcrystalline powder; ^{1}H-NMR (DMSO-*d$_6$*, 300 MHz) δ 12.95 (1H, s), 10.54 (1H, s), 7.59 (2H, s), 7.48–7.45 (2H, m), 7.44–7.36 (5H, m), 7.33–7.29 (5H, m), 6.94 (2H, d, *J* = 8.8 Hz), 6.22 (1H, s), 5.16 (2H, s), 5.06 (2H, s); ^{13}C-NMR (DMSO-*d$_6$*, 125 MHz) δ 192.0, 160.2, 159.7, 157.7, 153.2, 143.0, 136.7, 136.6, 134.4, 130.3, 128.5, 128.4, 128.3, 128.2, 128.0, 127.8, 127.4, 124.6, 115.2, 109.0, 99.7, 75.7, 69.4; HR–ESI–MS *m/z* 486.1983 [M + H]$^+$ (calcd. for C$_{30}$H$_{24}$D$_3$O$_6$, 486.1990).

4′-Benzyloxy-6-methoxy-5-benzyloxy-7-hydroxyflavone (**25a**). To a solution of compound **24a** (598 mg, 1.2 mmol) in dry DMSO (100 mL) was added I$_2$ (32 mg, 0.1 mmol) in DMSO (3 mL) dropwise by syringe. The resulting solution was heated to 120 °C, and stirred for 2 h. After cooling to rt, saturated

Na$_2$S$_2$O$_{3(aq)}$ (10 mL) was added to the reaction mixture. The mixture was diluted with EtOAc (100 mL) and wash with distilled H$_2$O (3 × 50 mL). The organic layer was dried over Na$_2$SO$_4$, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc:*n*-hexane = 1:3) to give **25a** (555 mg, 93%), a yellow microcrystalline powder; ^{1}H-NMR (DMSO-d_6, 300 MHz) δ 10.76 (1H, s), 7.98 (2H, d, *J* = 8.9 Hz), 7.61 (2H, d, *J* = 7.0 Hz), 7.48 (2H, d, *J* = 7.0 Hz), 7.44–7.34 (6H, m), 7.18 (2H, d, *J* = 8.9 Hz), 6.91 (1H, s), 6.67 (1H, s), 5.22 (2H, s), 5.00 (2H, s), 3.75 (3H, s); ^{13}C-NMR (DMSO-d_6, 125 MHz) δ 175.8, 160.9, 160.1, 156.1, 153.8, 150.7, 139.6, 137.6, 136.6, 128.5, 128.3, 128.1, 128.0, 127.8, 123.4, 115.3, 111.4, 106.0, 100.1, 75.6, 69.5, 60.9; HR–ESI–MS *m*/*z* 481.1637 [M + H]$^+$ (calcd. for C$_{30}$H$_{25}$O$_6$, 481.1646).

4′-Benzyloxy-6-[^{2}H$_3$]methoxy-5-benzyloxy-7-hydroxyflavone (**25b**). Following the procedure as described for compound **25a**, reaction of compound **24b** (849 mg, 1.7 mmol) with I$_2$ (44 mg, 0.2 mmol) in DMSO (120 mL) gave compound **25b** (664 mg, 79%), a yellow microcrystalline powder; ^{1}H-NMR (DMSO-d_6, 300 MHz) δ 10.75 (1H, s), 7.98 (2H, d, *J* = 8.9 Hz), 7.61 (2H, d, *J* = 6.8 Hz), 7.48 (2H, dd, *J* = 1.8, 8.4 Hz), 7.44–7.34 (6H, m), 7.18 (2H, d, *J* = 8.9 Hz), 6.91 (1H, s), 6.67 (1H, s), 5.22 (2H, s), 5.01 (2H, s); ^{13}C-NMR (DMSO-d_6, 125 MHz) δ 175.8, 160.9, 160.1, 156.1, 153.7, 150.7, 139.5, 137.6, 136.6, 128.5, 128.3, 128.1, 128.0, 127.8, 123.4, 115.3, 111.4, 106.0, 100.1, 75.6, 69.5; HR–ESI–MS *m*/*z* 484.1827 [M + H]$^+$ (calcd. for C$_{30}$H$_{22}$D$_3$O$_6$, 484.1834).

Hispidulin. To a solution of compound **25a** (301 mg, 0.6 mmol) in dry CH$_2$Cl$_2$ (40 mL) was added 1 M BCl$_3$ (2.5 mL, 2.5 mmol) in dry CH$_2$Cl$_2$ (5 mL) dropwise by syringe at −78 °C over 20 min. The resulting solution was stirred for 1 h. The reaction mixture was diluted with distilled H$_2$O (50 mL) and washed with EtOAc (3 × 50 mL). The organic layer was dried over Na$_2$SO$_4$, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc:*n*-hexane = 1:2) to give hispidulin (160 mg, 85%), a yellow microcrystalline powder; ^{1}H-NMR (DMSO-d_6, 500 MHz) δ 13.07 (1H, s, 5-OH), 10.73 (1H, s, 7-OH), 10.38 (1H, s, 4′-OH), 7.92 (2H, d, *J* = 8.9 Hz, H-2′, H-6′), 6.92 (2H, d, *J* = 8.9 Hz, H-3′, H-5′), 6.77 (1H, s, H-3), 6.59 (1H, s, H-8), 3.74 (3H, s, 6-OMe); ^{13}C-NMR (DMSO-d_6, 125 MHz) δ 182.2 (C-4), 163.9 (C-2), 161.2 (C-4′), 157.3 (C-7), 152.8 (C-5), 152.4 (C-9), 131.4 (C-6), 128.5 (C-2′, C-6′), 121.2 (C-1), 116.0 (C-3′, C-5′), 104.1 (C-10), 102.4 (C-3), 94.3 (C-8), 60.0 (6-OMe); HR–ESI–MS *m*/*z* 301.0702 [M + H]$^+$ (calcd. for C$_{16}$H$_{13}$O$_6$, 301.0707).

d-Hispidulin. Following the procedure as described for hispidulin, reaction of compound **25b** (536 mg, 1.1 mmol) in CH$_2$Cl$_2$ (75 mL) with 1 M BCl$_3$ (4.4 mL, 4.4 mmol) in CH$_2$Cl$_2$ (8.8 mL) gave *d*-hispidulin (268 mg, 80%), a yellow microcrystalline powder; ^{1}H-NMR (DMSO-d_6, 500 MHz) δ 13.07 (1H, s, 5-OH), 10.70 (1H, s, 7-OH), 10.36 (1H, s, 4′-OH), 7.91 (2H, d, *J* = 8.9 Hz, H-2′, H-6′), 6.92 (2H, d, *J* = 8.9 Hz, H-3′, H-5′), 6.76 (1H, s, H-3), 6.58 (1H, s, H-8); ^{13}C-NMR (DMSO-d_6, 125 MHz) δ 182.1 (C-4), 163.8 (C-2), 161.2 (C-4′), 157.2 (C-7), 152.8 (C-5), 152.4 (C-9), 131.3 (C-6), 128.5 (C-2′, C-6′), 121.2 (C-1), 116.0 (C-3′, C-5′), 104.1 (C-10), 102.4 (C-3), 94.2 (C-8); HR–ESI–MS *m*/*z* 304.0888 [M + H]$^+$ (calcd. for C$_{16}$H$_{10}$D$_3$O$_6$, 304.0895).

3.3. Human Liver Microsome Stability Assay

Mixed-gender human liver microsomes (Lot # 1210347) were purchased from XenoTech. The reaction mixture minus NADPH was prepared as described below. The test compounds were added into the reaction mixture at a final concentration of 1 μM. A separate reaction with the control compound, testosterone, was run simultaneously with the reactions with the test compounds. An aliquot of the reaction mixture (without cofactor) was equilibrated in a shaking water bath at 37 °C for 3 min. After addition of cofactor to initiate the reaction, the mixture was incubated in a shaking water bath at 37 °C. Aliquots (100 μL) were withdrawn at 0, 10, 20, 30 and 60 min for the test compounds and testosterone. The reaction was terminated by immediately combining the tested compounds and testosterone samples with 400 μL of ice-cold 50/50 acetonitrile (ACN)/H$_2$O containing 0.1% formic acid and internal standard. The samples were then mixed and centrifuged to precipitate proteins. All samples were assayed by LC-MS/MS using electrospray ionization. The peak

area response ratio (PARR) to internal standard was compared to the PARR at time 0 to determine the percent remaining at each time point. The values for half-life ($t_{1/2}$) and intrinsic clearance (CL_{int}) of the tested compounds were determined by Absorption System Corp. Half-life calculated using GraphPad software was fitted to a single-phase exponential decay equation.

Supplementary Materials: The following are available online. ^{1}H- and ^{13}C-NMR spectra and HPLC chromatogram of all compounds synthesized; ^{1}H- and ^{13}C-NMR spectra comparison of experimental and reported hispidulin; ROESY spectra of compound **21**; and ROESY, HMQC and HMBC spectra of final products hispidulin and *d*-hispidulin.

Author Contributions: Liang-Chieh Chen, Kai-Cheng Hsu, Hui-Ju Tseng and Wei-Jan Huang conceived and designed the experiments; Liang-Chieh Chen and Hui-Ju Tseng performed the experiments; Liang-Chieh Chen, Kai-Cheng Hsu and Wei-Jan Huang analyzed the data; Liang-Chieh Chen, Lih-Chu Chiou, Kai-Cheng Hsu and Wei-Jan Huang wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1.　Grassi, D.; Desideri, G.; Ferri, C. Flavonoids: Antioxidants against atherosclerosis. *Nutrients* **2010**, *2*, 889–902. [CrossRef] [PubMed]

2.　Pietta, P.G. Flavonoids as antioxidants. *J. Nat. Prod.* **2000**, *63*, 1035–1042. [CrossRef] [PubMed]

3.　Serafini, M.; Peluso, I.; Raguzzini, A. Flavonoids as anti-inflammatory agents. *Proc. Nutr. Soc.* **2010**, *69*, 273–278. [CrossRef] [PubMed]

4.　Cushnie, T.P.; Lamb, A.J. Antimicrobial activity of flavonoids. *Int. J. Antimicrob. Agents* **2005**, *26*, 343–356. [CrossRef] [PubMed]

5.　Cardenas-Rodriguez, N.; Gonzalez-Trujano, M.E.; Aguirre-Hernandez, E.; Ruiz-Garcia, M.; Sampieri, A., III; Coballase-Urrutia, E.; Carmona-Aparicio, L. Anticonvulsant and antioxidant effects of *Tilia americana* var. *mexicana* and flavonoids constituents in the pentylenetetrazole-induced seizures. *Oxid. Med. Cell. Longev.* **2014**, *2014*, 329172. [CrossRef] [PubMed]

6.　Guan, L.P.; Liu, B.Y. Antidepressant-like effects and mechanisms of flavonoids and related analogues. *Eur. J. Med. Chem.* **2016**, *121*, 47–57. [CrossRef] [PubMed]

7.　Ravishankar, D.; Rajora, A.K.; Greco, F.; Osborn, H.M. Flavonoids as prospective compounds for anti-cancer therapy. *Int. J. Biochem. Cell Biol.* **2013**, *45*, 2821–2831. [CrossRef] [PubMed]

8.　Fan, P.C.; Huang, W.J.; Chiou, L.C. Intractable chronic motor tics dramatically respond to *Clerodendrum inerme* (L) Gaertn. *J. Child Neurol.* **2009**, *24*, 887–890. [CrossRef] [PubMed]

9.　Huang, W.J.; Lee, H.J.; Chen, H.L.; Fan, P.C.; Ku, Y.L.; Chiou, L.C. Hispidulin, a constituent of *Clerodendrum inerme* that remitted motor tics, alleviated methamphetamine-induced hyperlocomotion without motor impairment in mice. *J. Ethnopharmacol.* **2015**, *166*, 18–22. [CrossRef] [PubMed]

10.　Liao, Y.H.; Lee, H.J.; Huang, W.J.; Fan, P.C.; Chiou, L.C. Hispidulin alleviated methamphetamine-induced hyperlocomotion by acting at alpha6 subunit-containing GABAA receptors in the cerebellum. *Psychopharmacology* **2016**, *233*, 3187–3199. [CrossRef] [PubMed]

11.　Cui, B.; Lee, Y.H.; Chai, H.; Tucker, J.C.; Fairchild, C.R.; Raventos-Suarez, C.; Long, B.; Lane, K.E.; Menendez, A.T.; Beecher, C.W.; et al. Cytotoxic sesquiterpenoids from Ratibida columnifera. *J. Nat. Prod.* **1999**, *62*, 1545–1550. [CrossRef] [PubMed]

12.　Iwashina, T.; Kamenosono, T.; Ueno, T. Hispidulin and nepetin 4 -glucosides from Cirsium oligophyllum. *Phytochemistry* **1999**, *51*, 1109–1111. [CrossRef]

13.　Flamini, G.; Antognoli, E.; Morelli, I. Two flavonoids and other compounds from the aerial parts of *Centaurea bracteata* from Italy. *Phytochemistry* **2001**, *57*, 559–564. [CrossRef]

14.　Fullas, F.; Hussain, R.A.; Chai, H.B.; Pezzuto, J.M.; Soejarto, D.D.; Kinghorn, A.D. Cytotoxic constituents of Baccharis gaudichaudiana. *J. Nat. Prod.* **1994**, *57*, 801–807. [CrossRef] [PubMed]

15.　Kavvadias, D.; Monschein, V.; Sand, P.; Riederer, P.; Schreier, P. Constituents of sage (Salvia officinalis) with in vitro affinity to human brain benzodiazepine receptor. *Planta Med.* **2003**, *69*, 113–117. [CrossRef] [PubMed]

16. Hall, B.J.; Karim, N.; Chebib, M.; Johnston, G.A.; Hanrahan, J.R. Modulation of ionotropic GABA receptors by 6-methoxyflavanone and 6-methoxyflavone. *Neurochem. Res.* **2014**, *39*, 1068–1078. [CrossRef] [PubMed]

17. Ren, L.; Chan, W.M.; Wang, F.; Xu, Z.; Zhao, C.; Mat, W.K.; Chai, Y.; Wong, J.T.; Tsang, S.Y.; Xue, H. Effects of flavone 6-substitutions on GABAA receptors efficacy. *Eur. J. Pharmacol.* **2011**, *670*, 121–129. [CrossRef] [PubMed]

18. Kavvadias, D.; Sand, P.; Youdim, K.A.; Qaiser, M.Z.; Rice-Evans, C.; Baur, R.; Sigel, E.; Rausch, W.D.; Riederer, P.; Schreier, P. The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. *Br. J. Pharmacol.* **2004**, *142*, 811–820. [CrossRef] [PubMed]

19. Shi, Z.H.; Li, N.G.; Wang, Z.J.; Tang, Y.P.; Dong, Z.X.; Zhang, W.; Zhang, P.X.; Gu, T.; Wu, W.Y.; Yang, J.P.; et al. Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo. *Eur. J. Med. Chem.* **2015**, *106*, 95–105. [CrossRef] [PubMed]

20. Lin, H.; Zhang, W.; Dong, Z.X.; Gu, T.; Li, N.G.; Shi, Z.H.; Kai, J.; Qu, C.; Shang, G.X.; Tang, Y.P.; et al. A new and practical synthetic method for the synthesis of 6-O-methyl-scutellarein: One metabolite of scutellarin in vivo. *Int. J. Mol. Sci.* **2015**, *16*, 7587–7594. [CrossRef] [PubMed]

21. Chao, S.W.; Su, M.Y.; Chiou, L.C.; Chen, L.C.; Chang, C.I.; Huang, W.J. Total Synthesis of Hispidulin and the Structural Basis for Its Inhibition of Proto-oncogene Kinase Pim-1. *J. Nat. Prod.* **2015**, *78*, 1969–1976. [CrossRef] [PubMed]

22. Shen, M.Z.; Shi, Z.H.; Li, N.G.; Tang, H.; Shi, Q.P.; Tang, Y.P.; Yang, J.P.; Duan, J.A. Efficient Synthesis of 6-O-methyl-scutellarein from Scutellarin via Selective Methylation. *Lett. Org. Chem.* **2013**, *10*, 733–737. [CrossRef]

23. Zhang, W.; Dong, Z.X.; Gu, T.; Li, N.G.; Zhang, P.X.; Wu, W.Y.; Yu, S.P.; Tang, Y.P.; Yang, J.P.; Shi, Z.H. A new and efficient synthesis of 6-O-methylscutellarein, the major metabolite of the natural medicine scutellarin. *Molecules* **2015**, *20*, 10184–10191. [CrossRef] [PubMed]

24. Katsnelson, A. Heavy drugs draw heavy interest from pharma backers. *Nat. Med.* **2013**, *19*, 656. [CrossRef] [PubMed]

25. Gant, T.G. Using deuterium in drug discovery: Leaving the label in the drug. *J. Med. Chem.* **2014**, *57*, 3595–3611. [CrossRef] [PubMed]

26. Mullard, A. FDA approves first deuterated drug. *Nat. Rev. Drug Discov.* **2017**, *16*, 305. [CrossRef] [PubMed]

27. Tung, R.D. Deuterium medicinal chemistry comes of age. *Future Med. Chem.* **2016**, *8*, 491–494. [CrossRef] [PubMed]

28. Labib, S.; Hummel, S.; Richling, E.; Humpf, H.U.; Schreier, P. Use of the pig caecum model to mimic the human intestinal metabolism of hispidulin and related compounds. *Mol. Nutr. Food Res.* **2006**, *50*, 78–86. [CrossRef] [PubMed]

29. Xu, H.J.; Liang, Y.F.; Cai, Z.Y.; Qi, H.X.; Yang, C.Y.; Feng, Y.S. CuI-nanoparticles-catalyzed selective synthesis of phenols, anilines, and thiophenols from aryl halides in aqueous solution. *J. Org. Chem.* **2011**, *76*, 2296–2300. [CrossRef] [PubMed]

30. Anderson, K.W.; Ikawa, T.; Tundel, R.E.; Buchwald, S.L. The selective reaction of aryl halides with KOH: Synthesis of phenols, aromatic ethers, and benzofurans. *J. Am. Chem. Soc.* **2006**, *128*, 10694–10695. [CrossRef] [PubMed]

31. Chen, J.M.; Yuan, T.J.; Hao, W.Y.; Cai, M.Z. Simple and efficient CuI/PEG-400 system for hydroxylation of aryl halides with potassium hydroxide. *Catal. Commun.* **2011**, *12*, 1463–1465. [CrossRef]

32. Kantevari, S.; Yempala, T.; Yogeeswari, P.; Sriram, D.; Sridhar, B. Synthesis and antitubercular evaluation of amidoalkyl dibenzofuranols and 1H-benzo[2,3]benzofuro[4,5-e][1,3]oxazin-3(2H)-ones. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4316–4319. [CrossRef] [PubMed]

33. Hase, T.; Ohtani, K.; Kasai, R.; Yamasaki, K.; Picheansoonthon, C. Revised Structure for Hortensin, a Flavonoid from Millingtonia-Hortensis. *Phytochemistry* **1995**, *40*, 287–290. [CrossRef]

Sample Availability: Samples of the compounds **12**, **32**, **33**, **34**, **35**, **36**, **37**, **38**, **41**, **42**, **43**, **44**, **45a**, **45b**, **46a**, **46b**, **47a**, **47b**, hispidulin and *d*-hispidulin are available from the authors.